Etoposide
- TRADE NAMES: Aside; Etopos; Etosid; Lastet; Serozide; VePesid (Bristol-Myers Squibb); Vepeside; VP-TEC
- INDICATIONS: Lymphomas, carcinomas
- CLASS: Topoisomerase 2 inhibitor
- HALF-LIFE: 4–11 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aldesleukin, Atovaquone, Atovaquone/Proguanil, Cyclosporine, Gadobenate, Prednisolone, St John's Wort
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 09/08/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric